Medicus Pharma Q3 2026 net loss per share narrows 79% to $11.64
MDCX•Medicus Pharma’s third-quarter 2026 net loss narrowed 5% year over year to $15.2 million. Net loss per share narrowed 79% to $11.64.
1. Quarterly results and priorities
Medicus Pharma reported a third-quarter 2026 net loss of $15.2 million, down 5% year over year. General and administrative expenses fell 50% to $2.5 million, while research and development spending rose 18% to $2 million. After a Pfizer licensing agreement, CD228V became the principal development priority, with an initial clinical proof-of-concept focus in melanoma. SkinJect entered a nonbinding agreement for a proposed SPAC combination contemplating an approximately $135 million pre-money enterprise valuation.
